Investors

We are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate the therapeutic function and direct the fate of hematopoietic cells.

Stock Quote

Price

$4.37

Change

+ 0.05

High

$4.45

Delayed at least 20 minutes.

Stock Chart